Poland· PL-100517123
Tivdak
A tisotumab vedotin product containing tisotumabi vedotinum, registered in Poland by Genmab A/S. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Tisotumab vedotin is registered in 10 of 19 countries.
Countries holding a registration under ATC L01FX23 (tisotumab vedotin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Tisotumab vedotin · ATC L01FX23
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Tisotumabi vedotinum
- Manufacturer
- Genmab A/S
- Country
- Poland (PL)
- ATC code
- L01FX23
- ATC class
- Tisotumab vedotin
- Defined daily dose
- 6.67 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tisotumab vedotin in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTivdak 40 mgGenmab
- CzechiaTIVDAKGENMAB A/S, Valby
- SpainTIVDAK 40 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONGenmab A/S
- FinlandTivdakGenmab A/S
- United KingdomTivdak 40mg powder for concentrate for solution for infusion vialsGenmab A/S
- IrelandTivdak 40 mg powder for concentrate for solution for infusionGenmab A/S
- IcelandTivdakGenmab A/S
- SwedenTivdak 40 mg Pulver till koncentrat till infusionsvätska, lösningGenmab A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tivdak
- Liechtenstein · Tivdak
- Norway · Tivdak
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6080e144-6911-432e-b3e1-0a991fddc5d2 GET /v1/drugs/6080e144-6911-432e-b3e1-0a991fddc5d2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania koncentratu roztworu do infuzji",
"source": "urpl",
"strength": "40 mg",
"packaging": "Rpz ¦ EU/1/25/1911/001 ¦ 161536\n1 fiol. 40 mg proszku",
"substance": "Tisotumabi vedotinum 40 mg",
"common_name": "Tisotumabi vedotinum",
"pl_product_id": "100517123",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about tisotumab vedotin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.